Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Not Just A Tweak: UK Review Seeks Sea Change In Drug Development

This article was originally published in Scrip

Executive Summary

The UK government's Accelerated Access Review is planning to bring big and meaningful changes to the way drugs are developed and brought to UK patients and is not just a tweak to the system. So says, Dr Stuart Dollow, chief executive and founder of Vermilion Life Sciences, who is helping to lead the review.

You may also be interested in...



Is International Reference Pricing Still Relevant?

International reference pricing is becoming more irrelevant as increasing emphasis is placed on other cost-containment measures.

Regulators Call for More Harmonization On Ultra-Rare ATMPs

Early discussions between companies and multiple regulators could drive greater alignment among jurisdictions.

Can The UK Remain A First Launch Market?

More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.

UsernamePublicRestriction

Register

SC029451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel